Bone Transport Enhances Diabetic Foot Ulcer Healing via TGF-β1 Coupling

Study Background and Research Question

Diabetic foot ulcers (DFUs) represent a major clinical complication in diabetes mellitus, with a prevalence of 15–25% among diabetic patients and a significant risk for infection, necrosis, and amputation. Despite advances in both conservative and surgical therapies, effective management of extensive or recalcitrant ulcers remains challenging, especially when peripheral arterial disease and local ischemia are present. Bone transport (BT), a surgical method originally developed for bone lengthening and defect repair, is known to stimulate both osteogenesis and angiogenesis. However, the molecular mechanisms by which BT may accelerate wound healing—particularly the role of transforming growth factor-beta 1 (TGF-β1) signaling—had not been fully elucidated prior to the work of Yan Chen and colleagues.

Key Innovation from the Reference Study

The reference study, published in Journal of Molecular Histology (2026), systematically investigates how bone transport accelerates diabetic foot ulcer healing through TGF-β1–mediated angiogenic and osteo-immune coupling. The central innovation lies in demonstrating that BT not only prompts local tissue regeneration but also orchestrates systemic immune and vascular changes through the activation of the TGF-β1/TGFBR1 signaling axis. This coupling of bone-derived signals with vascular and immune responses establishes a mechanistic framework for understanding how surgical biomechanical stimuli can be harnessed to improve chronic wound outcomes.

Methods and Experimental Design Insights

The experimental design leveraged a robust ischemic DFU rat model. Seventy-five Sprague-Dawley rats with induced diabetic foot ulcers were randomized into three groups:

• Sham group: Underwent osteotomy without distraction (serving as surgical control).
• BT group: Underwent bone transport surgery (distraction osteogenesis).
• BTI group: Underwent BT with pharmacological inhibition of the TGF-β1 pathway.

Wound healing was assessed via serial measurement, histological analysis, and molecular profiling. Proteomics, ELISA, RT-qPCR, and immunohistochemistry were used to quantify the activity of TGF-β1 signaling components and related pro-healing factors such as VEGF and α-SMA. Importantly, the BTI group allowed the authors to directly interrogate the necessity of TGF-β1 signaling in the observed healing processes.

Protocol Parameters

• Animal model: Sprague-Dawley rats with surgically induced ischemic diabetic foot ulcers; randomization into three groups (sham, BT, BTI).
• Bone transport procedure: Osteotomy followed by gradual distraction to induce new bone formation and associated tissue responses.
• TGF-β1 pathway inhibition: Pharmacological inhibitor administered to BTI group (details on dosing and inhibitor selection referenced in the original article).
• Healing assessment: Serial wound area measurement, evaluation of dermal thickness, re-epithelialization, and histological scoring at defined time points.
• Molecular analysis: Proteomic screening, ELISA for serum factor quantification, RT-qPCR and immunohistochemistry for tissue-level expression of TGF-β1, TGFBR1, VEGF, and α-SMA.

Core Findings and Why They Matter

BT-treated rats exhibited significantly accelerated wound closure, increased dermal thickness, and more advanced re-epithelialization compared to both sham and BTI groups. Proteomic and immunohistochemical analyses revealed upregulation of TGF-β1 and its receptor TGFBR1 in BT wounds, indicating pathway activation. Serum levels of TGF-β1 and VEGF were also elevated, alongside increased local expression of angiogenic and myofibroblastic markers (VEGF, α-SMA).

Crucially, these pro-healing effects were markedly diminished in the BTI group, confirming a central role for TGF-β1/TGFBR1 signaling in mediating the reparative benefits of bone transport. The study also found evidence of systemic immune modulation, including complement activation and regulation of both innate and adaptive immunity, linking BT-induced bone remodeling to broader tissue repair mechanisms through the TGF-β1 axis. This positions TGF-β1 not only as an angiogenic mediator but also as a pivotal coordinator of “osteo-immune” crosstalk during wound healing.

Comparison with Existing Internal Articles

The findings from this reference study align with and substantiate results discussed in related literature. For example, "Bone Transport Accelerates Diabetic Foot Ulcer Healing via TGF-β1" and "Bone Transport Enhances Diabetic Wound Healing via TGF-β1 Coupling" both underscore the significance of TGF-β1/TGFBR1 activation in coupling angiogenesis with osteo-immune modulation. These internal articles reinforce the mechanistic role of TGF-β1 signaling in reparative processes and further highlight the therapeutic promise of targeting this pathway in chronic wound models.

Moreover, resources such as "SB525334 and TGF-β1 Inhibition: Advancing Wound Healing Models" provide strategic guidance for applying TGF-beta1 receptor inhibitors in translational models, directly connecting the mechanistic insights from bone transport studies to practical laboratory workflows in fibrosis and wound healing research.

Limitations and Transferability

Despite the compelling evidence, several limitations must be considered. The study employs a rat model, which—while highly informative—may not fully recapitulate human diabetic wound biology or the complexity of clinical comorbidities. The pharmacological inhibition of TGF-β1 was performed in a controlled experimental context, and the specific inhibitor dosing or off-target effects were not exhaustively characterized. Additionally, the long-term consequences of modulating TGF-β1 signaling, particularly in the context of chronic disease or repeated tissue injury, remain to be explored.

Transferability to human wound healing will require validation in larger preclinical models and, eventually, clinical studies. The findings, however, provide a strong rationale for further investigating the TGF-β1 pathway as a therapeutic target in chronic wounds, as well as for refining surgical protocols that synergize biomechanical and molecular regenerative cues.

Research Support Resources

For researchers aiming to dissect TGF-β1 pathway dynamics in wound repair or fibrosis, small-molecule inhibitors such as SB525334 (TGF-beta1 receptor inhibitor) (SKU A5602) are valuable tools. SB525334 is a potent and selective inhibitor of the TGF-β type I receptor kinase (ALK5), enabling precise modulation of TGF-β1-induced Smad2/3 phosphorylation and downstream signaling. According to the product information, this inhibitor has been used to model TGF-β1 pathway inhibition in both cellular and animal systems, supporting mechanistic studies of fibrosis and tissue repair. APExBIO provides detailed specifications and storage guidelines to optimize experimental reproducibility. Incorporating SB525334 into wound healing or fibrosis research models can thus facilitate translational studies that build upon the mechanistic insights provided by the reference study and related literature.